Innovations for Next-Generation Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the i...
Uloženo v:
| Médium: | Elektronický zdroj E-kniha |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
Cham :
Springer International Publishing,
2018.
|
| Vydání: | 1st ed. 2018. |
| Edice: | Cancer Drug Discovery and Development,
|
| Témata: | |
| ISBN: | 9783319781549 |
| ISSN: | 2196-9906 |
| On-line přístup: |
|
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 003 | SK-BrCVT | ||
| 005 | 20220618100844.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180529s2018 gw | s |||| 0|eng d | ||
| 020 | |a 9783319781549 | ||
| 024 | 7 | |a 10.1007/978-3-319-78154-9 |2 doi | |
| 035 | |a CVTIDW10530 | ||
| 040 | |a Springer-Nature |b eng |c CVTISR |e AACR2 | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Innovations for Next-Generation Antibody-Drug Conjugates |h [electronic resource] / |c edited by Marc Damelin. |
| 250 | |a 1st ed. 2018. | ||
| 260 | 1 | |a Cham : |b Springer International Publishing, |c 2018. | |
| 300 | |a VIII, 357 p. 70 illus., 52 illus. in color. |b online resource. | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9906 | |
| 500 | |a Medicine | ||
| 505 | 0 | |a Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology. | |
| 516 | |a text file PDF | ||
| 520 | |a Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients. | ||
| 650 | 0 | |a Cancer research. | |
| 650 | 0 | |a Molecular biology. | |
| 856 | 4 | 0 | |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-78154-9 |y Vzdialený prístup pre registrovaných používateľov |
| 910 | |b ZE07810 | ||
| 919 | |a 978-3-319-78154-9 | ||
| 974 | |a andrea.lebedova |f Elektronické zdroje | ||
| 992 | |a SUD | ||
| 999 | |c 235875 |d 235875 | ||